We conducted a genome-wide association study of oral cavity and pharyngeal cancer in 6,034 cases and 6,585 controls from Europe, North America and South America. We detected eight significantly associated loci (P < 5 × 10 −8 ), seven of which are new for these cancer sites. Oral and pharyngeal cancers combined were associated with loci at 6p21.32 (rs3828805, HLA-DQB1), 10q26.13 (rs201982221, LHPP) and 11p15.4 (rs1453414, OR52N2-TRIM5). Oral cancer was associated with two new regions, 2p23.3 (rs6547741, GPN1) and 9q34.12 (rs928674, LAMC3), and with known cancer-related loci-9p21.3 (rs8181047, CDKN2B-AS1) and 5p15.33 (rs10462706, CLPTM1L). Oropharyngeal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele imputation showed a protective association with the class II haplotype HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 (odds ratio (OR) = 0.59, P = 2.7 × 10 −9 ). Stratified analyses on a subgroup of oropharyngeal cases with information available on human papillomavirus (HPV) status indicated that this association was considerably stronger in HPV-positive (OR = 0.23, P = 1.6 × 10 −6 ) than in HPV-negative (OR = 0.75, P = 0.16) cancers.
l e t t e r s
We conducted a genome-wide association study of oral cavity and pharyngeal cancer in 6,034 cases and 6,585 controls from Europe, North America and South America. We detected eight significantly associated loci (P < 5 × 10 −8 ), seven of which are new for these cancer sites. Oral and pharyngeal cancers combined were associated with loci at 6p21.32 (rs3828805, HLA-DQB1), 10q26.13 (rs201982221, LHPP) and 11p15.4 (rs1453414, OR52N2-TRIM5). Oral cancer was associated with two new regions, 2p23.3 (rs6547741, GPN1) and 9q34.12 (rs928674, LAMC3), and with known cancer-related loci-9p21.3 (rs8181047, CDKN2B-AS1) and 5p15.33 (rs10462706, CLPTM1L). Oropharyngeal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele imputation showed a protective association with the class II haplotype HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 (odds ratio (OR) = 0.59, P = 2.7 × 10 −9 ). Stratified analyses on a subgroup of oropharyngeal cases with information available on human papillomavirus (HPV) status indicated that this association was considerably stronger in HPV-positive (OR = 0.23, P = 1.6 × 10 −6 ) than in HPV-negative (OR = 0.75, P = 0.16) cancers.
Cancers of the oral cavity (OC) and oropharynx (OPC) are predominantly caused by tobacco and alcohol use, although oral infection with HPV, particularly HPV16, is an increasingly important cause of OPC 1 , especially in the United States and northern Europe 1,2 . The proportion of HPV-related OPC cases varies widely and is estimated to be approximately 60% in the United States, 30% in Europe and lower in South America [2] [3] [4] [5] . Genetic factors have also been implicated in OC and OPC susceptibility, especially polymorphisms within alcohol-related genes, including ADH1B (alcohol dehydrogenase 1B) and ADH7 (alcohol dehydrogenase 7) 6, 7 . To identify additional susceptibility loci, 13,107 individuals from 12 epidemiological studies ( Supplementary Table 1 ) were genotyped using the Illumina OncoArray; after stringent quality control steps (Online Methods and Supplementary Table 2 ), 6,034 cases and 6,585 cancer-free controls remained for analyses ( Table 1) . We next performed genomewide imputation using the Haplotype Reference Consortium panel 8 and obtained approximately 7 million high-quality imputed variants ( Supplementary Fig. 1) . Given the ancestry diversity of our study, we evaluated associations separately for each continent (Europe, North America and South America) using multivariate unconditional logistic regressions under a log-additive genetic model adjusted for age, sex and regional eigenvectors. Results by continent were combined using fixed-effects meta-analyses to derive associations for overall OC and pharynx cancer (oral, oropharynx, hypopharynx and overlapping cancers; n = 6,034), as well as site-specific OC (n = 2,990) and OPC (n = 2,641). Although several ancestry groups are present in the study, supervised ancestry analyses indicated that >90% of participants were predominantly of European (>70% CEU) ancestry, although some population admixture was observed in South America ( Supplementary Table 3 ).
Genome-wide association meta-analyses of overall and site-specific cancers identified nine regions at genome-wide significance (P < 5 × 10 −8 ) ( Fig. 1) . Quantile-quantile plots of observed versus expected P values showed moderate genomic inflation (λ) for the three metaanalyses (λ range = 1.04-1.06; Supplementary Figs. 2 and 3) . As λ increases with sample size, we scaled it to 1,000 cases and controls, resulting in ameliorated inflation (λ 1,000 range = 1.009-1.01) 9 . Overall OC and pharynx cancer were associated with rs79767424 (5p14.3), rs1229984 (4q23), rs201982221 (10q26.13), rs1453414 (11p15.4) and 123 SNPs at 6p21.32 ( Supplementary Table 4 ). Twenty-six variants were associated (P < 5 × 10 −8 ) with OC ( Supplementary Table 5 ), with 4 mapping to 2p23.3, 1 mapping to 4q23, 3 mapping to 9q34.12, 13 mapping to 5p15.33 and 5 mapping to 9p21.3. For OPC, new significant variants were located at 6p21.32 (62 SNPs; Supplementary Table 6 ). Suggestive susceptibility variants (P < 5 × 10 −7 ; Supplementary Tables 7-9) were associated with OC at four additional loci-6p21.33, 6p21.32, 15q21.2 and 15q26.2-and with OPC at 2q36.1. Other genomic locations outside the HLA region showed promising associations (P < 5 × 10 −6 ) with OPC ( Supplementary Table 10 ). For susceptibility loci at P < 5 × 10 −8 , functional annotations of regulatory features with Encyclopedia of DNA Elements (ENCODE) and expression quantitative trait locus (eQTL) information, if available, l e t t e r s l e t t e r s are summarized in Supplementary Tables 11 and 12 . Given the geographic heterogeneity of our population, we performed sensitivity analyses after excluding individuals with <70% CEU ancestry; these analyses gave similar results ( Supplementary Table 13 ). To validate array genotypes and imputed dosages, we directly genotyped at least one variant within each locus (P = 5 × 10 −7 ) in a subset of approximately 700 individuals using a different platform (TaqMan). The concordance between genotyped or imputed genotypes and TaqMan results was >97% for all regions, with the exception of rs2398180, an imputed variant that had concordance of 94% ( Supplementary  Tables 14 and 15 ). TaqMan assays could not be designed for two rare variants, rs201982221 (10q26.13) and rs7976742 (5p14.3), and we used Sanger sequencing for validation ( Supplementary Table 16 ).
We were able to validate the rs201982221 deletion (Online Methods), but rs7976742 did not validate (Online Methods). The lead variants at each validated locus (P < 5 × 10 −8 ) for overall and site-specific analyses are shown in Table 2 . Results stratified by geographical region, smoking and alcohol status are displayed in Figure 2 (oral and pharynx cancer combined) and Figure 3 (oral cancer). The association at rs1229984 (4q23, ADH1B) has previously been reported as a susceptibility locus for OC and OPC 6 ; as in previous findings, this variant showed heterogeneity by region, smoking status and alcohol drinking status 10, 11 (Fig. 2a) . Three other 4q23 SNPs reached P < 5 × 10 −8 , although conditional analyses indicated that these are not independent signals ( Supplementary  Table 17 ). The rs1573496 (ADH7) variant reported to be strongly associated with OC and OPC in the previous genome-wide association study (GWAS) for upper aerodigestive tract cancer 7 l e t t e r s only moderately associated here ( Supplementary Table 18 ). In the overall OC and pharynx cancer analysis, we identified rs201982221 at 10q26.13 (OR = 1.67, P = 1.58 × 10 −9 ), which was also separately associated with OC (OR = 1.71, P = 1.04 × 10 −7 ) and OPC (OR = 1.70, P = 7.9 × 10 −7 ) (Fig. 2b) . rs201982221 is located in the LHPP gene in a region with reported regulatory features ( Supplementary  Table 11 ). However, it is a rare intronic deletion in an area of low linkage disequilibrium (LD) (Supplementary Fig. 4 ) and thus warrants further validation in a different population. rs1453414, the lead signal at 11p15.4 (Supplementary Table 19) , is an intronic variant that showed borderline association in the overall (OR = 1.19, P = 4.78 × 10 −8 ) and site-specific (OC (OR = 1.19, P = 1.65 × 10 −5 ) and OPC (OR = 1.22, P = 4.26 × 10 −6 )) analyses ( Fig. 2c and Supplementary Fig. 5 ). rs1453414 is upstream of OR52N2, which encodes an olfactory receptor, and within TRIM5, which encodes an E3 ubiquitin ligase, and is an eQTL for these genes in brain tissue 12 ( Supplementary Table 12 ). At 2p23.3, four SNPs showed evidence (P < 5 × 10 −8 ) of association with OC and in conditional analyses did not appear to be independent ( Supplementary Table 20 ). These signals map to an area with high LD that includes C2orf16, ZNF512, CCDC121 and GPN1 (Supplementary Fig. 6 ). The lead SNP, rs6547741, was associated with OC but not with OPC and maps to an intron of GPN1, which encodes a GTPase involved in RNA polymerase II transport and DNA repair 13 . Associations between rs6547741 and OC were homogenous across other analyses stratified by region, sex, smoking status and drinking status (Fig. 3a) .
Variation at 5p15.33 was also exclusively associated with OC susceptibility (OPC: rs10462706, P = 0.47). The top signal, rs10462706, was associated with decreased OC risk (OR = 0.74, P = 5.54 × 10 −10 ) and is Overall OR = 1.28, P = 4 × 10 Overall OR = 1.16, P = 7 × 10 The effect allele appears in square brackets. "Overall" denotes results for oral and pharyngeal cancer. l e t t e r s in low LD (r 2 = 0.15; Supplementary Fig. 7) with the second strongest signal, rs467095. These two variants are 7 kb apart and map to intron 13 of CLPTM1L. In stratified analysis, they showed stronger effects in never smokers (heterogeneity P value (P het ) = 0.07 and 0.0028, respectively) and never drinkers (P het = 0.01 and 0.0025, respectively) ( Fig. 3b  and Supplementary Fig. 8) . Conditional analyses showed that these SNPs were not completely independent ( Supplementary Table 21 ). TERT and CLPTM1L encode telomerase reverse transcriptase (TERT) and the cleft lip and palate-associated transmembrane 1-like protein (CLPTM1L), respectively. Notably, rs467095 is an esophageal eQTL for TERT 14 ( Supplementary Table 12 ) and is in high LD with rs401681 (OR = 1.18, P = 2.1 × 10 −7 , r 2 = 0.94), a widely studied SNP associated with risk of several cancers, including: lung 15, 16 , bladder, prostate, cervical, melanoma 17 , basal cell 18 , esophageal 19 , pancreatic 20 and nasopharyngeal 21 cancers. Multiple 5p15.33 variants have been reported to independently influence cancer risk, both increasing and decreasing risk. Interestingly, rs401681[A] was associated with increased OC risk, similar to previous melanoma associations and in the opposite direction to previous lung cancer results 17 . Several variants within the CDKN2A-CDKN2B locus (9p21.3) were found to be associated with OC. The lead SNP, rs8181047, is an intronic variant within CDKN2B-AS1 (CDKN2B antisense RNA 1) ( Fig. 3c) . rs8181047 is in LD (range r 2 = 0.6-0.8) with four other 9p21.3 variants strongly associated with OC ( Supplementary Fig. 9 ) that in conditional analyses did not show independent associations (Supplementary Table  22 ). The CDKN2A-CDKN2B locus contains genes involved in cell cycle regulation and senescence and has been associated with multiple malignancies, including melanoma 22 , glioma 23 , basal cell 18 , breast 24 , lung 25 , nasopharyngeal 26 and esophageal 27 cancers. Notably, CDKN2A is frequently mutated in HPV-negative head and neck cancers 28 .
The OC-associated variants at 9q34.12 mapped to an intron of LAMC3, which encodes a laminin involved in cortical development 29 . rs928674, the peak signal, showed consistent effects across strata and a weaker association with OPC (P = 0.003) (Fig. 3d) . rs928674 is in high LD with three other robustly associated 9q34.12 SNPs (range r 2 = 0.82-0.96; Supplementary Fig. 10 and Supplementary Table 23 ) and is an esophageal mucosa cis-eQTL for a downstream gene, AIF1L (allograft inflammatory factor 1 like) 14 .
The most prominent finding in the overall and OPC meta-analyses was a strong association signal at 6p21.32 within the HLA class II region. The lead variant in both analyses, rs3828805, maps 1.7 kb 5′ of HLA-DQB1 ( Fig. 2d and Supplementary Fig. 11 ) and, similar to other 6p21.32 variants (Supplementary Tables 4 and 6) , showed heterogeneity in effect by geographic region (P het = 0.007) with no effect in South America (P = 0.62). Association analyses of 6p21.32 variants (P < 5 × 10 −8 ) conditioned on rs3828805 did not show multiple independent signals (Supplementary Table 24) , suggesting a common haplotype. To further investigate HLA associations, we imputed classical alleles in 11,436 individuals (with >70% European ancestry) (Online Methods). Three classical HLA alleles, HLA-DRB1*1301, HLA-DQA1*0103 and HLA-DQB1*0603, reached P < 5 × 10 −8 in the overall analysis and were also strongly associated with OPC ( Supplementary Table 25 ). These alleles are in high LD (r 2 >0.9) and are part of the HLA class II haplotype HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603, which is common in Europeans and was previously reported to be associated with decreased cervical cancer risk 30 . The HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 haplotype was strongly associated with reduced OPC risk (OR = 0.59, P = 2.7 × 10 −9 ) and was more weakly associated with OC risk (OR = 0.75, P = 1.7 × 10 −4 ). Further conditional analysis on this haplotype and 6p21.32 variants did not show evidence of additional independent effects ( Supplementary Table 26 ). Given the importance of HPV infection in the etiology of cervical and oropharyngeal cancers 31 , we conducted post-hoc analyses to examine the effect of HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 haplotype in a subset of 576 cases with information available on HPV status and 3,662 controls. HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 was associated with strongly reduced risk of HPVpositive OPC (OR = 0.23, P = 1 × 10 −6 , n = 336), with no significant association in 240 HPV-negative OPC cases (OR = 0.75, P = 0.16) ( Table 3 ). These results indicate that the class II HLA region is implicated in at least two HPV-driven cancers, namely HPV-positive OPC and cervical cancer. The lack of an association between 6p21.3 SNPs and OPC risk in South America could relate to previous findings that less than 10% of OPC cases are positive for HPV in this region 4, 5 . Moreover, weaker association with OC could be due to a smaller proportion of the cases being positive for HPV, as well as to some OPC cases possibly being misclassified, especially for tumors at the base of the tongue. Further evaluation of the extent and specificity of this HLA effect in HPV-associated cancers is important given the strength l e t t e r s of the observed association. Such evaluation may help elucidate why some individuals are at higher risk of HPV-positive OPC after HPV infection and may also have implications for cancer immunotherapies targeting the HLA class II antigen presentation pathway 32 .
In summary, we identified seven oral and pharyngeal cancer susceptibility loci, including a strong HLA signal narrowed to a class II haplotype. Future replication of these findings in an independent population is warranted, as well as fine-mapping and functional studies necessary to establish the biological framework underlying these associations. 
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Methods and any associated references are available in the online version of the paper. Accession codes. Genotype data for the oral and pharyngeal OncoArray study have been deposited at the database of Genotypes and Phenotypes (dbGaP) under accession phs001202.v1.p1.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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